Form 4 for CRL Charles River Laboratories
Accepted 2024-06-04 00:00:00 ET · period of report 2024-05-31 · accession 0001127602-24-017674 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-04 | 2024-05-31 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $0.00 | +3,838 | 50.5K | +8% | $0 |
| D | 2024-06-04 | 2024-05-31 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $208.44 | +8,722 | 8,722 | New | +$1.82M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-31 | A | A | 3,838 | $0.00 | 50,512 | D | — | — | (F1) Unvested restricted stock units vest as follows: 959 on May 31, 2025, 960 on May 31, 2026, 959 on May 31, 2027, and 960 on May 31, 2028. |
| 2 | Derivative | Stock Options (Right to Buy) | 2024-05-31 | A | A | 8,722 | $208.44 | 8,722 | D | $208.44 · 2025-05-31 to 2034-05-31 | 8,722 Common Stock | (F2) Stock options vest as follows: 2,180 on May 31, 2025, 2,181 on May 31, 2026, 2,180 on May 31, 2027, and 2,181 on May 31, 2028. |